Last reviewed · How we verify
Sovateltide
At a glance
| Generic name | Sovateltide |
|---|---|
| Also known as | IRL-1620, PMZ 1620, Tycamzzi™, Tyvalzi™, PMZ-1620 |
| Sponsor | Pharmazz, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy (PHASE2)
- Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke (PHASE4)
- Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke (PHASE3)
- PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury (PHASE2)
- PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients (PHASE2)
- Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke (PHASE3)
- PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease (PHASE2)
- Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |